Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intuitive Surgical

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering of up to $50 mil. in common stock is outlined in a preliminary prospectus filed with the Securities and Exchange Commission. Founded in November 1995, the Mountain View, California company is developing a tele-robotic instrumentation system for minimally invasive surgery. The device's three components include a surgeon's control console with 3D visual display, patient-side cart that holds electromechanical instrument manipulators, and surgical instruments designed for use through small (1 cm) incisions. Although Intuitive, which plans initially to pursue cardiac surgery indications, has already gained 510(k) clearance for the console, patient-side cart and "certain blunt resposable instruments," regulatory clearance for certain other instruments is necessary prior to commercialization, the firm explains. A clinical trial is slated to begin in July under a March investigational device exemption in order to obtain data requested by FDA for use of the instruments in certain thoracoscopic and laparoscopic surgical procedures. Net proceeds from the IPO are tabbed for continued R&D, clinical trials, manufacturing scale-up, expansion of marketing and sales capabilities, and other corporate purposes. Morgan Stanley Dean Witter, Bear Stearns and BT Alex. Brown are underwriters for the offering
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010019

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel